文献速递血栓与止血贫血与红细胞疾病

COVID-19的血液学表现与并发症

Hematological findings and complications of COVID-19.
PubMed 文献 · Am J Hematol · 2020-05-23

本文综述COVID-19对造血系统与止血系统的影响:淋巴细胞减少可能是核心实验室发现并具预后价值,中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值亦有预后意义;住院患者血液高凝常见,D-二聚体升高与病情恶化相关,需警惕DIC并推荐早期、延长低分子肝素药物性血栓预防。

要点

  • 淋巴细胞减少可能是COVID-19的核心实验室发现,并具预后潜力。
  • 中性粒细胞/淋巴细胞比值与血小板/淋巴细胞比值可能有助于判断重症。
  • 住院COVID-19患者血液高凝常见,推荐早期并延长低分子肝素血栓预防。

核心结论

  • COVID-19是累及造血系统与止血的系统性感染,淋巴细胞减少可能是核心实验室发现并具预后潜力。
  • 住院COVID-19患者血液高凝常见,D-二聚体升高与病情恶化相关。
  • COVID-19患者无论住院或门诊均有静脉血栓栓塞高风险,推荐早期并延长低分子肝素药物性血栓预防。

研究设计与样本

  • 本文为综述,检索范围未在原文/摘要中报告。

主要发现

  • 淋巴细胞减少可能是核心实验室发现,具预后潜力。
  • 中性粒细胞/淋巴细胞比值与峰值血小板/淋巴细胞比值可能对判断重症有预后价值。
  • 病程中连续评估淋巴细胞计数动态及LDH、CRP、IL-6等炎症指标可能有助于识别预后不良者。
  • 血清降钙素原与铁蛋白升高也作为不良预后因素出现。
  • D-二聚体升高被一致报告,病程中逐渐升高尤其与病情恶化相关。

关键数值与推荐

  • 凝血异常包括PT与aPTT延长、纤维蛋白降解产物增加,伴严重血小板减少可导致危及生命的DIC。
  • 高凝与D-二聚体升高的具体数值、阈值原文/摘要未报告。

临床怎么用

  • 对住院或门诊COVID-19患者应警惕静脉血栓栓塞风险。
  • 推荐早期并延长使用低分子肝素进行药物性血栓预防。
  • 连续监测淋巴细胞计数、LDH、CRP、IL-6、降钙素原、铁蛋白及D-二聚体以辅助识别预后不良者。
  • 对PT、aPTT延长、纤维蛋白降解产物增加及严重血小板减少需持续警惕DIC并及时干预。
  • 疫情期间需保障献血供应。

局限性

  • 本文为综述,原文/摘要未报告系统检索策略、纳入研究数量及偏倚评估。
  • 原文/摘要未报告具体数值、阈值、剂量及样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020. PMID: 32282949. doi:10.1002/ajh.25829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。